Literature DB >> 7438692

Kinetics of hydralazine and its main metabolites in slow and fast acetylators.

P A Reece, I Cozamanis, R Zacest.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438692     DOI: 10.1038/clpt.1980.234

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  18 in total

1.  Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.

Authors:  P Brunel; J B Lecaillon; T T Guyene; P Imhof; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

3.  Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.

Authors:  P A Reece; I Cozamanis; R Zacest
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.

Authors:  D E Drayer
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

6.  Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.

Authors:  P A Reece; I Cozamanis; R Zacest
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Assay for hydralazine as its stable p-nitrobenzaldehyde hydrazone.

Authors:  H A Semple; Y K Tam; S Tin; R T Coutts
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

9.  Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.

Authors:  H A Semple; Y K Tam; R T Coutts
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

10.  The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.

Authors:  P A Meredith; H L Elliott; D R McSharry; A W Kelman; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.